两项研究显示更新的 COVID 疫苗可有效预防严重疾病
Two studies in US veterans find updated COVID vaccines protect against severe illness
两项涉及超过 100 万名美国退伍军人的研究表明,更新的 COVID 疫苗能显著降低严重疾病的风险。一项研究发现,2025-26 年疫苗将急诊就诊风险降低约 32%,住院风险降低约 44%。另一项研究显示,Moderna 疫苗在老年人中的保护效果优于 Pfizer 疫苗,减少医疗关注的 COVID 感染病例约 10 例/10,000 人,减少住院病例约 2 例/10,000 人。
Two new studies involving more than 1 million U.S. veterans suggest that updated COVID-19 vaccines continue to provide meaningful protection against severe illness.
One study, published in Vaccine, found that the 2025–26 vaccine reduced the risk of emergency department visits by approximately 32% and the risk of hospitalization by roughly 44%. The second study, published in JAMA Network Open, found that the 2025–26 Moderna vaccine offered greater protection against medically attended COVID among older adults than Pfizer's vaccine.
Vaccination tied to fewer emergency visits, hospitalizations
In the first study, a team led by researchers from the Veterans Affairs (VA) Saint Louis Health Care System analyzed data from 931,943 veterans who received a seasonal flu vaccine from Sept. 21, 2025, to Jan. 31, 2026. Of those, 114,911 received a COVID vaccine on the same day, while 817,032 received only the flu vaccine.
Over the course of 180 days, COVID vaccination was associated with a 31.7% reduction in COVID-related emergency department (ED) visits and a 43.6% decrease in hospitalizations. That translates to approximately seven fewer ED visits and roughly three fewer hospitalizations per 10,000 people.
While the researchers note that the absolute risk reductions were modest, the findings "quantify the benefit of vaccination in a lower-incidence season and can inform shared clinical decision making and seasonal vaccine policy," they write.
Moderna vaccine outperforms Pfizer's version
For the second study, researchers led by a team from VA Providence Healthcare System in Rhode Island compared Moderna's newer mRNA-1283 COVID vaccine with Pfizer/BioNTech's mRNA COVID vaccine among U.S. veterans aged 65 years or older to assess whether 2025–26 vaccination was associated with a lower risk of COVID infection that required medical attention.
Among the 294,499 participants, medically attended COVID occurred in 86 of 55,349 mRNA-1283 vaccine recipients (0.16%) and 672 of 239,150 Pfizer vaccine recipients (0.28%). That corresponds to a 35.9% greater relative vaccine effectiveness (VE) for the Moderna vaccine, or 10 fewer medically attended cases per 10,000 vaccinated people.
COVID-related hospitalization occurred in 11 mRNA-1283 vaccine recipients (0.02%), compared with 114 Pfizer vaccine recipients (0.05%). That represents a greater relative VE of 47.0% for the Moderna vaccine, or two fewer hospitalizations per 10,000 vaccinated people.
"The findings suggest that the mRNA-1283 vaccine may offer more clinically meaningful protection for older adults at high risk of severe COVID-19 outcomes and could inform seasonal vaccine selection," write the researchers.
Publication details
Yan Xie et al., Effectiveness of the 2025–2026 Covid-19 vaccine against Covid-19–associated emergency department visits and hospitalizations among U.S. veterans: An observational study, Vaccine (2027). DOI: 10.1016/j.vaccine.2026.129254
Kevin W. McConeghy et al., Estimation of mRNA-1283 vs BNT162b2 COVID-19 Vaccine Effectiveness in Older US Veterans, JAMA Network Open (2026). DOI: 10.1001/jamanetworkopen.2026.44727
Journal information: JAMA Network Open , Vaccine
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Two studies in US veterans find updated COVID vaccines protect against severe illness (2026, November 18) retrieved 18 November 2026 from https://medicalxpress.com/news/2026-11-veterans-covid-vaccines-severe-illness.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com